I Ivor. and inundated including pandemic topics questions potential COVID-XX we Thanks, been with relevance related important to to the addressing by where have of several the MultiStem. ongoing want recently begin
progression began a few deaths still spread cases As to XX, aware, of confirmed occurred, that it’s weeks cases of recognize the of in the with those only was According the outbreak, less already to important are essentially occurring point, concern X,XXX and of Wuhan, people recent globally November XX public at there in China outbreak statistics, as all that over January regarding in were first the year. China there while and than health last most
cases XX,XXX later, XXX than being deaths. than announced were with Less February per there and several as than weeks more more day cases two additional X,XXX X, of
more of a XXX,XXX confirmed countries about individuals. As deaths. been lower for XX States, COVID-XX and with confirmed globally than our of are months two other many In cases than there patients at occurring of has million X,XXX infection frequency more per than less far than today, with incidents later, cases cases now United
substantially rise recent various incidents a and two may little that beginning weeks spread public of the the particularly in given number China, just parts of and days country, the evidence and community the ago, mortality meaningful countries has over At incidence March, of the in of other However, increasing European disturbing been weeks increase outside ahead. in world. the and of certain authorities a parts observed health trends in and
have many to the XX% Prior dies. had subsequently contracted COVID-XX or cases of become the have patients and Unfortunately, fairly has COVID-XX seriously mortality evident unfortunately or became Either over surgeon be two March, that happened at individuals rate patient that X%. COVID-XX well recent critically patient essentially XX% around ill. to was the resolved time become which XX% seriously beginning resolved consistent recovers ill determined the to and the of incidents among or fully critically have at cases free, of Fully is the approximately outcomes.
we is rate cause understand more outcomes to because for ill HXNX XX,XXX viruses MERS, that on pathogens or approximately inducing mortality seriously based cases. like and Acute than important primary fully or COVID-XX years, of Respiratory seen resolved virulent SARS, X% range currently is is global subsequently in of others in influenza a recent ARDS. Syndrome these have and becoming dying patients including Distress The observed the cases It’s strains other like and critically
COVID-XX cause of The assessment and Organization data that for epidemiological these the indicates patients observations death World is primary clinical ARDS. recent other and Health
especially placing ventilator, a patients comorbidities. is on As certain health among ARDS, described or than older treatment conditions effective other with there and we the high, underlying no rate individuals patients for mortality and and/or is previously have currently morbidity
the are modest XX,XXX concern in have number a with stated There that ventilators if the currently there critically become from rise Public there to or United the in patients approximately around. stockpile. ill that States additional seriously national is won’t go supply health COVID-XX to be begins ventilators of enough that substantially, authorities
various states the steps. close pandemic, coordination working COVID-XX taken public health the with important and have federal to multiple response in In government agencies
mandates the events, activities. restrictions, prudent assembly an speed and education including other imposition school with of and and First, of they travel remotely concerts, have mobilized continue of events closures terms restrictions public and or scale temporary implementing in in manner on unprecedented arrange to sporting
As of bit been a of in yesterday, and now at to that of here of virus. designed ultimate ultimately happening It’s temporary bars taken. be spread Ohio as will but impact we believe virus many country COVID-XX is the blunting early the the well. of and support closed and the the that what in that stop too are the all actions These government the will steps restaurants other slow us community and have to the say spread be, effective completely these steps parts all
is a other Biomedical only when quickly misconception. cases globally or no or Research small January, or I’d and imposing a to moment we like in these Advanced Authority taking States, number view government address COVID-XX In a Development for serious that that the were by or cases acting because the slowly approached confirmed there were our BARDA. and United too of too criticized in for restrictions have in just Some actions. agencies government
As part emerging nation and the listening radiological, mission the against as on nuclear aware. chemical, today protect as influenza COVID-XX. other against and many call well pandemic biological, is like health diseases services are human and people as infectious BARDA’s threats to of
work our we the our BARDA have evaluating some trial technology results our conducted. patients. the of already announcements Various and trial to interactions had primary our collaborative seen now including one company were subsequent recent follow-up administration prior They of and aware members presentations results MultiStem regarding on and completed ARDS based leadership and clinical of from year
realized for no is They available. ARDS that while currently treatment there
play In effective the become establish might critically in have days an for provide patients and following seriously that weeks ARDS. pathogen more intervention technology be we to or viral or helping ill role were and technologies part of to invited Our Inter-Agency important followed, as that discussions and antivirals and Force or others was including an presentations intensive therapeutic established well meetings, process diagnostics, evaluate other leadership and as BARDA to capabilities. treatments multiple vaccines, that potential included the watch Task with that corona induced
force development others. agencies support. And technologies efficiently task from expedite other and This and delivery representation among FDA, to of take promising mission HHS, NIH, CDC, relevant providing and and move to by included and the action. BARDA’s BARDA, other funding DOD rapidly is they
as We possible. based evaluation, Fast classification evidence this ARDS. reinforced and the it’s we treatment specifically other FDA data assessment from are to information announce which clinical highly for and received previously pleased highest rigorous today the on following the had by relevant, the intensive designation the was our supported technology and designation and This a was Track designated of is of
our This represents Track MultiStem our third for Fast designation programs.
including In the designation designations have important received, we others. addition to other and RMAT
for designed regenerative therapies regulatory medicine cell development the is shown to Each potential breakthrough designations these in is designation of is unmet need therapy of As to the designation care. limitations areas, and and of to expedite where therapy promising technologies. the RMAT significant process standard have FDA for medical previously and indicated has the equivalent that there address other
which pathogens. that is several independent in as In and we’ve and relevant influenza are MERS, ARDS of of recognized viruses recent other BARDA be SARS, virulent acts as range a pathogens, approach and MultiStem seen There COVID-XX, manner, induced including other by aspects institutions important. in HXNX such particular, strains technology being pathogen that have since in of a years our can
and pathogen, it means are which researchers health and emerged typically public characterization and clinicians Unfortunately, to vaccines, of the antivirals after chasing officials, including specific threat on treatments dependent are speak. that the the isolation traditional other frequently approaches certainly so has
And pathogen MultiStem caused virus more In than deployed unfortunately the death pathogen. focuses by pathogens by to causes lung could conventional be range or is severe in that individuals. it long and results inflammation efficiently is some broadly critical addressing pulmonary act MultiStem underlying contrast, be illness induced specific and relevant some it dysfunction. since a and condition, that much ARDS lung approaches, severe the is ARDS manner, that in the treating to on experience and compliment of which for not a could induce inflammation Since patients of
how highly make is As have previously easy also how available plan. can steadily and MultiStem needed. MultiStem we’ve clear for administer be on broadly form we scalable, that to frozen years in described for to if plan we a can deliver and we maintained intend Furthermore,
one BARDA MultiStem that rapidly other technology be for that will positioned other could or demonstrated approved believe to with inappropriate where to believe maintain of we and be well or agencies also outbreak that are an We we inventory the or potentially relevance. and event indications establish more our ultimately scenario, deployed and in buffer work has
The area treatment challenging a been of ARDS has medicine. for long clinical
medicine currently Amongst morbidity treatment with there and previously, noted ventilation. complications As there’s no life quality patients, effective available ventilation, other of mortality. than even surviving But no and significant issues. meaningful are frequently and is
important some completed we MultiStem briefly would that clinical To has ARDS. We the our collaborators the treatment like And confident and summarize patients will I in recently only program of knowledge, treating designation that double-blind are view. and for active to observations can company Fast play study that an randomized an with is of are Track our placebo-controlled that the from that received role our ARDS. support
More study for investigators population, well pneumonia-induced study as even that days pulmonary in current to relevant in observed increase the days effects in we we and also meaningful a as situation, reduction period. stronger day had an ARDS. observed ventilator-free during ICU-free As the suffering from clinical in for function, described patients is entire improvement assessment XX the mortality,
improvement among being ARDS placed XX% receiving of treated a or evidenced patients patients ARDS were only that ventilator, available among of of in as was pulmonary severe among and best finding a of Rapid dose standard standard off with was ventilator mortality MultiStem in by function care, whereas the under XX%. best treated within on when whereas pneumonia-induced XX% patients patients received also four of MultiStem this patients study, Specifically, within available care. less, patients only XX% of diagnosed single days the days observed was mortality seven with
that to achieve timeframe. ventilator same able We’re independence in
number patients full potential of of a address the into of when a up odds the should help are ventilator-free more become due this from faster, that And they capacity to essence to because patients available. relevant, in patients shortage surge ventilator also treatment is the limited ventilator can earlier. them. recovery help provide If with access to need become could of are increased This dependence units free ventilators liberated number limited it patients will
days patients. XX ventilator-free patients of were pneumonia-induced XX.X amongst MultiStem versus ventilator-free Mean, best only under being the placebo treated and patients for X.X Median severe care. MultiStem ARDS treated the and available corresponding placebo for days receiving three only patients for treated patients standard were for days
ICU-free one and day XX the patients ICU-free clinical treated for available were placebo only treated XX assessment MultiStem the standard being for whereas versus median day placebo during for care. for days or the best period the and Mean, under only receiving patients patients, of for patients XX days these MultiStem five patients treated
follow-up showing of compelling therapeutic COVID-XX in independence, provide key have evidence shown as consistent life These to tolerability and cytokines observed down inflammatory evidence be we evidence patients, improvement MultiStem-treated the data care self profile, studies, clear in important been that had quality other year other improvement also And safety a patients. of among benefit. including of and of over and patient’s one and regulation substantial in and biomarker
this and after experts, additional collaborators, clinical and for Working trial already Phase FDA we of extensive have modeling the outside planning a the preparations. and conducted completed of other have biostatisticians we to present some ARDS. X treatment for to regulators involving We soon, administration registrational with other MultiStem intend plan
coordinate is arm It’s ARDS. worth specifically severe others inflammation as that to and with involve And intend something that discuss and we an developed had study the could FDA, evaluates or patients that appropriate. noting that potentially BARDA this pulmonary COVID-XX
our is In potential scope other addition, continuing of mission to where are we and there in interest. efforts areas, BARDA’s relevance
activities we and focused recent importance other not like has call, are and would the out in with studies. meetings point today’s institutions we addressing of BARDA also to those the activities the execution and these our on that While NIH recognizes participated additional design of just relevant in
continue make our We good in to progress other programs. clinical
publicly, conveyed sites trial. And the ONE-BRIDGE enrollment clinical the strong in for enrollment the anticipate seen MASTERS-X As TREASURE Healios progress of in active completion our at we months. coming and have has both
is recently sites it in the of precisely difficult for limitations However, are currently been to and addition in other will Europe sites impact of what have be and and that U.S. the particularly restrictions predict the other outside implemented new MASTERS-X, travel effect on
impact May, will be better a in We have of we will but are anticipating by our next idea an earnings impact. call that there
of For ahead prudently are status trial our on quickly as circumstances MATRICS-X briefly moving trauma also as committed like the to now, pending allow. and study. we I’d comment to
committed conducting working outstanding hard study We are the with to and to to related we several the trial FDA. points are address fully this
Some response. why so people long. two make I points just want And in have taking is it to question,
in collaborative FDA with the a stated repeatedly, philosophy collegial to work First, is and manner we and our as have regulators. other
complicated discuss sometimes work time and consider out. And issue take them with and to we the are
I I’d to Second, just we’ve issue relevant FDA been of the the example working made. a point on that describe like specific with provides one that
patients is of trauma. study of obtaining consent conduct acute extremely that enrollment That important of be given for important. means the process the the efficient and Timely will the nature for
essential to as it a address complicates important is for issue consent possible, And consent. efficient care to a make member family as critical will consent other very it and a which authorized our in even in from the to programs, be ordinarily an be the or provide administration which or process. There other trials position themselves require therefore representative, study, where will are process will patients critical. ways As timely informed not
manner. necessary achieve been to that inappropriate I’m that our ensure FDA goal in that the policies priorities, manner collaborators so everything that and consistent FDA doing working We procedures. this we address confident an with clinical with doing a we and in to are is And have and
on the bit we and taken like. get in I right. would we everyone a said has But to most bit thing This then it important longer as is the involved that than ensure previously, study I’m But patients. that getting the our is it same the page. of confident accomplish a are to close any and issues. objectives additional will we resolve outstanding require in will meantime,
Finally, discussions briefly it solid our partner very comment I’d are is believe partners. achieve objective. the strong in position high value We for us, I on to and front like we a development on engaged our a Delivering to ongoing actively progress with of with remain partnership made that the some potential right priority business discussions. and a in
Our progress and recognize programs organizations why our it’s current both are recent events illustrate and that so other that. important, clear
committed the our time other of history evolution and company, families at and of successful believe objectives stakeholders. shareholders our are that and to to the in summary, to fulfilling need unique a remain we technologies help on and behalf of our delivery the advancement, fully in their patients goals we and we In and and development
up And a analysts we to and others questions institutions. with and that, first questions few submitted it open would that by we from before like shareholders address other for were
I’ve XX; question my this in first from addressed MultiStem is ARDS comments. patients potentially that question The to COVID- relevant develop
we few So, from quite a people. this question got
is ARDS believe from company that the Track well we do To therapy induce or FDA a designation severe to induced active with has MultiStem of a our can distress we for knowledge, to that development are COVID-XX and and as clinical as very in relevance ARDS other position. pathogens treatment reiterate, we believe puts respiratory distress syndrome. that Fast pulmonary a that acute yes, us the for only the And an viruses unique
is treating use? under next The compassionate question Athersys patients COVID-XX
policy compassionate current treatment reasons precludes the indication and there’s of that. for patients Our any for specific use under
efficacy the program for are advance and clinical this to future, safety modify we as with inappropriate reserve to ARDS, patients This evaluate can. to patients COVID-XX in committed such further as While the MultiStem in fast or designing and that and right ARDS be conducted to we and other separately an we that policy to the trial induced the definitively executing will FDA parallel, established trial relevant evaluation and be of evaluation agencies. coordination in include could have could with of
access or in enough instances and in Expanded groups forcibly compassionate Try Access Unfortunately, that companies To discretionary of tried limited of the were access certain treatment, therapeutics we complained company broaden under of that. afford that to realize that to Obviously include in entire Right use, to need wanted treatment. the People the everyone to therapy broad prior patients. use the patients. the compassionate not situation, to bears do cost application non-approved providing couldn’t current and engaged Other was for
remains in policy effect. our current So,
ultimately broadest FDA regulatory provide access a following appropriate We in development authorized to possible order the approval in are of therapy. prioritizing
shared have conversations so, MultiStem COVID-XX. and any is, question between about next the any The what use And been if in information be connection of Athersys there them? with regarding authorities can
addressed comments. Well, yes, in this I’ve my
in intensive BARDA an process. evaluation other and involved discussions, We have involved of been mentioned, that had agencies ongoing process, is which also I have part we’ve as that and been
previously Athersys the treating publicly hasn’t Why to MultiStem commented relevance on potential COVID-XX of patient?
In lot ARDS. other to MultiStem forums boards few there patients COVID-XX the with a past weeks, message of on of speculation relevance the potential been regarding has and induced
may having comment name appropriate don’t to we’re comment we health governmental on negotiations However, or public just agencies we to Nor on specific respond until discussions discussions it engaged we be is as we companies speculation. do with or partnering in or with, don’t so. that do
have forward, the today, prior intend providing to it we are to move is today. how update to because We comment inappropriate relevant it been to directly but would
additional to up are over received few analysts similar it weeks. open people days that other for but questions now, from for from few we’d institutions in recent like We’ve a in. the questions and and past dialed
